Aspergillus fumigatus, lethal fungus spreading across US raises alarm — Florida, Texas, California & more states at risk
The fungus causes aspergillosis, a serious lung infection that can lead to organ failure and death, particularly in cancer, asthma, or HIV patients. As the news report notes, its spores are so small they are inhaled without notice. Once inside the lungs, the fungus can trigger chronic infections or even spread to the brain, heart, and kidneys in more invasive forms.
Despite its danger, aspergillosis is not a reportable disease in the US — meaning infections, hospitalizations, and fatalities are not systematically tracked, making outbreaks difficult to identify.
Citing health data, the news outlet reported that invasive aspergillosis hospitalisations in the US rose by around 3% annually between 2000 and 2013. By 2014, nearly 15,000 hospital stays were linked to the infection, costing an estimated $1.2 billion. Intensive care autopsies also revealed it ranks among the top four infections most likely to cause death.
Around 400,000 people are estimated to suffer from chronic pulmonary aspergillosis, the long-term form of the disease. Invasive cases, though less common, are far more fatal — with only 59% of organ transplant patients surviving a year after infection, and just 25% of stem cell transplant patients, according to studies cited by The Daily Mail.
The fungus thrives in warm, damp environments and can survive temperatures above 120°F in compost piles. According to The Daily Mail, the highest exposure levels are being recorded in Florida, Louisiana, Texas, Georgia, and California — states with hot, humid climates and extensive farming activity. Dense urban centers like New York, Houston, and Los Angeles are also vulnerable due to aging infrastructure and population density.
A University of Manchester study warned, the news report stated, that if fossil fuel use continues unchecked, Aspergillus fumigatus could expand by over 75% by 2100, putting millions more at risk across the southern US.
Perhaps most concerning is the rising drug resistance. Azole antifungal drugs — commonly used to treat human infections — are also widely applied in agriculture to protect crops. Experts cited by the news outlet said that this practice may be driving environmental resistance, with drug-resistant fungal spores jumping from soil to humans.
A study in Applied and Environmental Microbiology found azole-resistant strains of Aspergillus fumigatus in farm soils across at least seven US states. Some strains are resistant to multiple standard treatments, and the mixing of fungal types may be accelerating the resistance crisis.
The World Health Organization has named Aspergillus fumigatus a "critical priority" due to its high mortality rates and the increasing threat of untreatable infections. The news outlet reported that the WHO is urging global investment in new antifungal drugs, faster diagnostic tools, improved hospital protocols, and enhanced training for healthcare professionals. The organization is also calling on pharmaceutical firms to include children in clinical trials for fungal treatments.
Doctors are advising those with compromised immune systems to avoid gardening, soil, and moldy environments, wear protective masks in dusty areas, and ensure clean air circulation in hospitals and homes. US hospitals have begun strengthening mold inspections and antifungal protocols in response to the growing concern.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
8 hours ago
- The Hindu
T.N. becomes first state in the country to integrate ‘predicted possibility of TB deaths' among patients into its elimination programme
To reduce the average time from diagnosis to hospital admission for severely ill tuberculosis (TB) patients Tamil Nadu has become the first state in the country to integrate a model, which predicts the possibility of TB deaths among patients, with the existing state-wide application which screens them at diagnosis. The predictive model, developed by the ICMR National Institute of Epidemiology (ICMR-NIE), which was launched last week and will aid the State in bringing down the TB mortality rate said Asha Frederick, State TB Officer of Tamil Nadu. She added that the predictive death model has been developed using data from nearly 56,000 TB patients diagnosed in public health facilities across Tamil Nadu between July 2022 and June 2023. Globally, India has the highest burden of TB with two deaths occurring every three minutes. But these deaths can be prevented. With proper care and treatment, TB patients can be cured, notes the World Health Organisation. Research further adds that TB is among the leading causes of morbidity and mortality worldwide, and more than 70% of the deaths of TB patients occur during the first two months of treatment. Speaking about the addition of the new feature in the Tamil Nadu TB elimination programme Dr. Frederick explained that this new addition will merge with the existing TB SeWA (Severe TB Web Application) which has been in use since 2022 under the state's differentiated care model initiative Tamil Nadu - Kasanoi Erappila Thittam (TN-KET). 'What this new feature will do is to alert frontline staff on how to recognise a severely ill TB patient – from a given list of medical indications including body weight, ability to stand without support, etc -- so that he is given priority in hospital admission and that treatment is initiated without delay. The predicted probability of death ranges widely — from 10% to as high as 50%, depending on how many of the five risk factors are present. In contrast, for patients not flagged as severely ill, the predicted probability drops sharply to just 1–4 per cent,' explained Hemant Shewade, a senior scientiat at NIE. He added that while the average time from diagnosis to admission of a TB patient in Tamil Nadu is one day, around a quarter of severely ill patients still face delays of up to six days in the state. All 2,800 public health facilities in Tamil Nadu — from primary health centres to medical colleges — currently use the TB SeWA application alongside a paper-based triage tool. Old age, TB/HIV co-infection and a baseline body weight of <35 kg increased the mortality during TB treatment, notes a study titled 'Time to Death and Associated Factors among Tuberculosis Patients in Dangila Woreda, Northwest Ethiopia', which adds that a special follow up of TB patients during the intensive phase, of older patients and TB/HIV co-infected cases, as well as nutritionally supplementing for underweight patients may be important to consider as interventions to reduce deaths during TB treatment.
The Hindu
14 hours ago
- The Hindu
Tamil Nadu first to integrate ‘predicted possibility of TB deaths' in patients to its State TB elimination programme
To reduce the average time from diagnosis to hospital admission for severely ill tuberculosis (TB) patients, Tamil Nadu has become the first State in the country to integrate a model that predicts the possibility of TB deaths among patients with the existing State-wide application which screens them at diagnosis. The predictive model, developed by the Indian Council of Medical Research (ICMR)-National Institute of Epidemiology (NIE) and launched last week, will aid the State in bringing down the TB mortality rate, Asha Frederick, State TB Officer, Tamil Nadu, said. The predictive death model has been developed using data from nearly 56,000 TB patients diagnosed in public health facilities across Tamil Nadu between July 2022 and June 2023, Dr. Frederick said. Research shows TB is among the leading causes of morbidity and mortality worldwide, and more than 70% of TB deaths occur in the first two months of TB treatment. Globally, India has the highest burden of TB, with two deaths occurring every three minutes from TB. These deaths can be prevented. With proper care and treatment, TB patients can be cured, the World Health Organization has said. The addition of the new feature in the Tamil Nadu TB elimination programme, Dr. Frederick said, would merge it with the existing TB SeWA (Severe TB Web Application), in use since 2022 under the Tamil Nadu Kasanoi Erappila Thittam (TN-KET) differentiated care model initiative. 'What this new feature will do is to alert frontline staff on how to recognise a severely ill TB patient from a given list of medical indications, including body weight, ability to stand without support, etc., so that they are given priority in hospital admissions, and treatment is initiated without delay. The predicted probability of death ranges widely — from 10% to as high as 50%, depending on how many of the five risk factors are present. In contrast, for patients not flagged as severely ill, the predicted probability drops sharply to just 1% to 4%,' Hemant Shewade, senior scientist at the NIE, said. The average time from diagnosis to admission of a TB patient in Tamil Nadu is one day, and around a quarter of severely ill patients still face delays of up to six days in the State, Dr. Shewade said. All 2,800 public health facilities in Tamil Nadu — from primary health centres to medical colleges — currently use the TB SeWA application alongside a paper-based triage tool. Old age, TB/HIV co-infection, and a baseline body weight of <35 kg increase mortality during TB treatment, a study titled 'Time to Death and Associated Factors among Tuberculosis Patients in Dangila Woreda, Northwest Ethiopia' has found. Special follow-ups of TB patients during the intensive phase, and of older patients and TB/HIV co-infected cases, as well as nutritionally supplementing underweight patients, may be important interventions to consider in order to reduce deaths during TB treatment.
Mint
2 days ago
- Mint
When an HIV Scientific Breakthrough Isn't Enough
(Bloomberg Opinion) -- A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food and Drug Administration last month. Gilead Sciences' lenacapavir is so effective that global health leaders had started to cautiously talk about the end of an epidemic that continues to kill more than 600,000 people each year. We should be celebrating its arrival. Instead, aid groups and the countries most affected by HIV are reeling from the Trump administration's relentless attacks on the global health infrastructure. Instead of perfecting plans for a rollout of the medication, they are scrambling to ensure people with HIV have the drugs they need to survive. Last year, I wrote about the stunning — or as one HIV expert described it, 'spine-chilling'— results from a large study of lenacapavir. None of the women and adolescents who were given the twice-yearly injection in the trial became infected with HIV. In a second study involving men who have sex with men, and transgender individuals who have sex with men, the treatment was 96% effective. Even better, Gilead is working on a newer version that could potentially offer protection for a year or more. That's about as close to an HIV vaccine we're likely to get — at least for many years. It's also the world's best shot of achieving the goal of ending HIV by 2030. For low- and middle-income countries that continue to face frustratingly stubborn infection rates, a twice-yearly drug could be a game-changer. Although existing treatments of daily pills do an excellent job at preventing infection, getting people to use them consistently has been difficult. There is the stigma attached to the pills. Ensuring patients return for frequent testing and refills is also challenging — as is simply remembering to take them daily. Consider the typical day of a mom with a newborn and it's easy to understand how six months of protection could make a real difference in lowering HIV cases in women and infants. Some experts have even suggested lenacapavir is our best chance of wiping out new infections in children. That was before the Trump administration abruptly shut down USAID, the lead agency behind Pepfar. The global initiative to combat HIV/AIDS is credited with saving an estimated 26 million lives since its inception in 2003. Although the administration granted a limited waiver to allow some HIV services to continue, funding is significantly restrained. As health workers grapple with fewer resources, their focus has shifted to people living with HIV. 'When the chips are down, you safeguard treatment because those people will die if they don't get their antiretroviral,' says Linda-Gail Bekker, director of the Desmund Tutu HIV Centre at the University of Cape Town. And yet, she said, 'prevention we know is an absolute cornerstone to bringing this epidemic under control.' Because the situation is so dynamic, it's been difficult to capture what's happening on the ground. The best current model suggests the administration's actions could result in at least 70,000 additional new infections, and another 5,000 deaths in the next five years. UCLA infectious disease epidemiologist Dvora Joseph Davey says that in 2024, the eight public health clinics in Cape Town — where she is based — saw three infants who were HIV-positive at birth. In the first five months of this year, they've already seen three babies born with the infection. She knows there will be more. One pregnant woman with HIV recently came into the clinic and, at 37 weeks, her viral load was dauntingly high. She'd skipped picking up her last three-month supply of pills. The nurse she'd been seeing was let go as part of the funding cuts, and no one was available to do a blood draw at her last visit, Davey says. If the people who, in theory, should still be benefiting from global aid are falling through the cracks, what hope do we have for prevention? Prevention efforts have already been severely disrupted in some countries. Supply is responsible for some of the upheaval, but the more complicated problem is getting the drugs to the people who need them most. 'We need low-cost product and also a low-cost delivery mode,' says Carmen Pérez Casas, senior strategy lead at Unitaid, a global health initiative hosted by the World Health Organization. The situation for the latter 'has changed radically,' she says. HIV prevention is not as simple as just handing out a prescription. It's first identifying those most at risk of infection, getting them tested to confirm they are negative, and offering counseling about their options. It's ensuring they return for more testing and the next dose of their medication. That requires a vast support network ranging from doctors and nurses to counselors, pharmacists, lab technicians, data scientists and more. Pepfar supported all of that infrastructure. In South Africa, for example, cuts have resulted in lost jobs for some 8,000 health workers focused on HIV. Aid groups are doing their best to ensure the breakthrough's promise is not entirely lost. Their first hurdle is bridging the gap to the arrival of low-cost generic lenacapavir, which isn't expected until sometime in 2027. (Gilead is allowing a handful of drug companies to make and sell generic forms of lenacapavir in the countries most heavily impacted by HIV.) Global health agencies are anxiously awaiting the company's price tag for those countries to understand how far their funding can be stretched. Then they need to get the drug to patients. Experts tell me they've scaled back their expectations given the upheaval with Pepfar. The Trump administration's termination of National Institutes of Health grants to foreign countries has created additional hurdles. It's been particularly devastating in South Africa, where the NIH supported a significant chunk of research related to HIV. That means less money to conduct so-called implementation studies for lenacapavir, which are crucial for understanding how to improve the drug's use in the real world. One simple thing the Trump administration could do is free up funding for prevention. Pepfar continues to operate under a waiver that only allows PrEP money to be spent for those who are pregnant or breastfeeding. Groundbreaking science alone won't end HIV. It must be paired with affordability and access. The Trump administration's callous cuts to global health efforts put all of those things at risk — including the promising future where HIV is brought to heel. More From Bloomberg Opinion: This column reflects the personal views of the author and does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners. Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry. Previously, she was executive editor of Chemical & Engineering News. More stories like this are available on
